Dark

Check out our Level2View

RGLS
Regulus Therapeutics Inc.
stock NASDAQ

Inactive

Jun 24, 2025

8.16USD+0.246%(+0.02)9,342,413

Pre-market

0.00USD-100.000%(-8.14)0

After-hours

0.00USD0.000%(0.00)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 21, 2022

08:08AM EST The Daily Biotech Pulse: Kura Lifts Clinical Hold On Blood Cancer Trial, Intuitive Surgical Earnings, Sorrento's Omicron Antibody Treatment Effective Benzinga

06:38AM EST Regulus Therapeutics Moves Forward With Next-Gen Compound, RGLS8429 In Kidney Disorder Benzinga

05:22AM EST Regulus Therapeutics Reports Successful Completion Of Pre-Investigational New Drug Meeting With FDA For RGLS8429 Benzinga

Jan 20, 2022

05:19PM EST Regulus Therapeutics Announces Successful Completion of Pre-IND Meeting with PR Newswire

Jan 4, 2022

08:01AM EST Regulus Therapeutics to Present at the H.C. Wainwright Virtual BioConnect PR Newswire

Dec 3, 2021

08:32AM EST Regulus Appoints Mohammad Ahmadian As VP Chemistry And Pharmaceutical Development RTTNews

08:31AM EST Regulus Appoints Mohammad Ahmadian, Ph.D., as Vice President, Chemistry and PR Newswire

Dec 1, 2021

08:33AM EST Regulus Therapeutics Announces Presentation At First Annual Rare & Genetic Kidney Disease Drug Development Summit Benzinga

08:31AM EST Regulus Therapeutics Announces Presentation at the First Annual Rare & Genetic PR Newswire

Nov 30, 2021

05:23PM EST Regulus Therapeutics Announces Closing of $34.6 Million Private Placement of PR Newswire

Nov 24, 2021

04:19PM EST Regulus Therapeutics Announces Private Placement Of Equity Of ~$34.6M Benzinga

04:05PM EST Regulus Therapeutics Announces Private Placement of Equity PR Newswire

Nov 10, 2021

06:08PM EST Regulus Therapeutics Q3 EPS $(0.10) Misses $(0.08) Estimate Benzinga

04:06PM EST Regulus Therapeutics Reports Third Quarter 2021 Financial Results and Recent PR Newswire

04:09AM EST Earnings Scheduled For November 10, 2021 Benzinga

Nov 9, 2021

12:00PM EST Regulus Therapeutics Granted US Patent 'Methods for treatment of polycystic kidney disease' Benzinga

Nov 3, 2021

05:15PM EDT Regulus Therapeutics Announces Timing for Third Quarter 2021 Financial Results PR Newswire

Oct 13, 2021

03:11PM EDT Mid-Afternoon Market Update: Nasdaq Jumps 100 Points; Jasper Therapeutics Shares Spike Higher Benzinga

01:39PM EDT Mid-Day Market Update: Gold Surges 2%; Neuronetics Shares Plunge Benzinga

01:38PM EDT The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal Benzinga

06:43AM EDT The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 06.15 A.M. EDT). RTTNews

Oct 12, 2021

04:09PM EDT Regulus Shares Were Halted With Code News Pending Ahead Of News On Strategic Prioritization Of Its Polycystic Kidney Disease Drug Candidate, Will Resume Trade At 4:35 p.m. EDT Benzinga

04:07PM EDT Regulus Therapeutics Reports Strategic Prioritization Of RGLS8429 Candidate For Treatment Of Autosomal Dominant Polycystic Kidney Disease Benzinga

04:05PM EDT Next-Generation Candidate for the Treatment of Autosomal Dominant Polycystic Kidney Disease PR Newswire

04:02PM EDT Regulus Therapeutics Shares Halted; New Pending Benzinga

Sep 30, 2021

04:56PM EDT Regulus Therapeutics' Director David Baltimore Receives 2021 Lasker-Koshland PR Newswire

Sep 9, 2021

04:41PM EDT Regulus Therapeutics to Present at the H.C. Wainwright 23rd Annual Global PR Newswire

Sep 2, 2021

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 2, 2021 Benzinga

08:29AM EDT Cantor Fitzgerald Initiates Coverage On Regulus Therapeutics with Overweight Rating, Announces Price Target of $2 Benzinga

Aug 10, 2021

04:57PM EDT Recap: Regulus Therapeutics Q2 Earnings Benzinga

04:57PM EDT Regulus Therapeutics Q2 EPS $(0.08), Inline Benzinga

04:06PM EDT Regulus Therapeutics Reports Second Quarter 2021 Financial Results and Recent PR Newswire

07:55AM EDT The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts Benzinga

04:05AM EDT Earnings Scheduled For August 10, 2021 Benzinga

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 3, 2021

05:15PM EDT Regulus Therapeutics Announces Timing for Second Quarter 2021 Financial Results PR Newswire

Jun 25, 2021

01:38PM EDT Regulus Therapeutics Presents Additional Data From Rare Kidney Disease Program Benzinga

07:32AM EDT The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs Benzinga

07:07AM EDT Regulus Therapeutics Presents Addl Data From ADPKD Program At PKD Connect 2021 RTTNews

07:07AM EDT Regulus Therapeutics To Present Additional Data From Autosomal Dominant Polycystic Kidney Disease Program At PKD Connect 2021 At 2-3 p.m. CDT. Benzinga

07:05AM EDT Regulus Therapeutics Presents Additional Data from its Autosomal Dominant PR Newswire

May 21, 2021

10:47AM EDT Regulus's Polycystic Kidney Disease Candidate Shows Benefit At Interim Analysis Benzinga

08:11AM EDT Regulus Therapeutics Report Incremental Update From First Cohort Of Patients With ADPKD In RGLS4326 Phase 1b Trial RTTNews

08:11AM EDT Regulus Therapeutics Announces Incremental Update Of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program Benzinga

08:07AM EDT Regulus Therapeutics Announces Incremental Update of Autosomal Dominant PR Newswire

May 14, 2021

04:07PM EDT Regulus Therapeutics to Present at the Oppenheimer Rare & Orphan Disease Summit PR Newswire

06:30AM EDT HC Wainwright & Co. Maintains Buy on Regulus Therapeutics, Raises Price Target to $2 Benzinga

May 13, 2021

04:47PM EDT Regulus Therapeutics Q1 EPS $(0.08) Beats $(0.09) Estimate Benzinga

04:07PM EDT Regulus Therapeutics Reports First Quarter 2021 Financial Results and Recent PR Newswire

08:10AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use Benzinga

04:15AM EDT Earnings Scheduled For May 13, 2021 Benzinga

May 6, 2021

05:15PM EDT Regulus Therapeutics Announces Timing for First Quarter 2021 Financial Results PR Newswire

May 3, 2021

09:26AM EDT Regulus Therapeutics' RGLS4326 Reports Mixed Bag On Polycystic Kidney Disease-Associated Biomarker Study Benzinga

08:16AM EDT Regulus Therapeutics Announces Top-Line Data From First Cohort Of Phase 1b Clinical Trial Of RGLS4326 RTTNews

08:07AM EDT UPDATE: Regulus Therapeutics Says 'Mean PC2 levels increased compared to baseline levels (>20%) however the results did not reach statistical significance.' Benzinga

08:05AM EDT Regulus Therapeutics Announces Top-Line Data From First Cohort Of Phase 1b Clinical Trial Of RGLS4326 For Autosomal Dominant Polycystic Kidney Disease; Says RGLS4326 Was Well Tolerated By All Nine Patients With No Serious Adverse Events Reported Benzinga

08:02AM EDT Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire

Apr 15, 2021

08:31AM EDT Regulus Therapeutics Completes Dosing In First Cohort Of Phase 1b Trial Of RGLS4326 For ADPKD RTTNews

08:22AM EDT Regulus Therapeutics Announces Completion of Dosing in the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease Benzinga

08:07AM EDT Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire

Apr 7, 2021

08:07AM EDT Regulus Therapeutics to Present at the 20th Annual Needham Virtual Healthcare PR Newswire

Mar 9, 2021

04:09PM EST Regulus Therapeutics Q4 Loss/share $0.03 Vs. Loss $0.23 Year Ago RTTNews

04:09PM EST Regulus Therapeutics Q4 EPS $(0.03) Up From $(0.23) YoY, Sales $5.00M Up From $18.00K YoY Benzinga

04:07PM EST Regulus Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results PR Newswire

Mar 5, 2021

04:07PM EST Regulus Therapeutics to Present at the H.C. Wainwright Global Life Sciences PR Newswire

Feb 18, 2021

08:14AM EST The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout Benzinga

Feb 10, 2021

08:11AM EST Regulus Completes Enrollment In First Cohort Of Phase 1b Trial Of RGLS4326 For Treatment Of Patients With ADPKD RTTNews

08:08AM EST Regulus Therapeutics Announces Completion Of Enrollment In First Cohort Of Phase 1b Clinical Trial Of RGLS4326 For The Treatment Of Patients With Autosomal Dominant Polycystic Kidney Disease Benzinga

08:07AM EST Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire

07:34AM EST The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs Benzinga

Jan 28, 2021

08:03AM EST The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO Benzinga

Jan 27, 2021

10:07AM EST Stocks That Hit 52-Week Highs On Wednesday Benzinga

08:17AM EST Regulus Adds Alice S. Huang, Ph.D. To Board Of Directors Benzinga

08:08AM EST Regulus Therapeutics Names Alice Huang To Board Of Directors RTTNews

08:07AM EST Regulus Announces Addition to Board of Directors PR Newswire

07:36AM EST The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement Benzinga

Jan 5, 2021

08:07AM EST Regulus Therapeutics to Present at the H.C. Wainwright Virtual BioConnect PR Newswire

Dec 8, 2020

08:27AM EST Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Dec. 8, 2020: VBK, EXAS, TSM, AMC, RGLS Benzinga

08:12AM EST Regulus Therapeutics Reports Closing Of $19.4M Private Placement; Dec. 1 Press Release Showed Expectation For Combined Common Stock And Warrants Price Of $0.7158/Share; Release From Today Shows $0.622 For Shares Plus $0.125 For Warrants Benzinga

08:07AM EST Regulus Therapeutics Announces Closing of $19.4 Million Private Placement of PR Newswire

05:20AM EST Regulus Therapeutics Shares Rise 10% Premarket; Scott Sandell Reported Purchase of 9,896,563 Shares @ Avg Price of $0.51/Share in Form 4 Filing Monday Benzinga

Dec 2, 2020

07:24AM EST Bio-Techne Corp. (TECH) and Regulus Therapeutics Inc. (RGLS) announced Wednesday a collaboration to support Regulus with biomarker analysis for the clinical development of RGLS4326, an Autosomal Dominant Polycystic Kidney Disease (ADPKD) treatment. RTTNews

07:11AM EST Regulus Therapeutics, Bio-Techne Collaborate For Biomarker Development RTTNews

07:09AM EST Regulus Therapeutics Collaborates With Bio-Techne For Biomarker Development Benzinga

Dec 1, 2020

08:39AM EST Regulus Therapeutics Reports $19.4M In Gross Proceeds From Private Placement Benzinga

08:35AM EST Regulus Therapeutics Announces Private Placement of Equity PR Newswire

Nov 5, 2020

05:36PM EST Regulus Therapeutics Q3 EPS $(0.04) Up From $(0.26) YoY, Sales $5.00M Up From $18.00K YoY Benzinga

04:07PM EST Regulus Therapeutics Reports Third Quarter 2020 Financial Results and Recent PR Newswire

Nov 2, 2020

08:11AM EST Regulus Announces Achievement Of Interim Enrollment Milestone In Sanofi Collaboration; To Get Remaining $5 Mln Payment RTTNews

08:11AM EST Regulus Therapeutics Achieves Interim Enrollment In Phase 2 Study Of RG-012 For Alport Syndrome, Triggering $5M Payment From Sanofi Collaboration Benzinga

08:07AM EST Regulus Therapeutics Announces Achievement of Interim Enrollment Milestone PR Newswire

Oct 15, 2020

08:14AM EDT Regulus Therapeutics Announces First Patient Dosed In Phase 1b Clinical Trial Of RGLS4326 For The Treatment Of Patients With Autosomal Dominant Polycystic Kidney Disease Benzinga

08:07AM EDT of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire

Oct 13, 2020

08:08AM EDT Regulus Therapeutics Announces Receipt Of $5M Milestone And Material Payments from Sanofi Benzinga

08:07AM EDT Regulus Therapeutics Announces Receipt of $5 Million Milestone and Material PR Newswire

Sep 11, 2020

08:07AM EDT Regulus Therapeutics to Present at the H.C. Wainwright 22nd Annual Virtual PR Newswire

Sep 3, 2020

08:07AM EDT Regulus Therapeutics to Present at the 2020 Wells Fargo Virtual Healthcare PR Newswire

Aug 31, 2020

08:17AM EDT Regulus Therapeutics Reports Restructuring Of Sanofi And Oxford Loan Agreements RTTNews

08:09AM EDT Regulus Therapeutics Restructures Loan Allowing for 7 Months of Interest Only Payments if the Company Pays Down $10M in Principal Before April 30, 2021 Benzinga

08:07AM EDT Regulus Therapeutics Announces Restructuring of Sanofi and Oxford Loan PR Newswire

Aug 28, 2020

10:20AM EDT 'Regulus Therapeutics has been awarded a $300,000 National Institutes of Health contract for research and development of antiviral drugs to cure chronic hepatitis B virus infection.' - TradeHawk Benzinga

Aug 13, 2020

04:15PM EDT Regulus Therapeutics Q2 EPS $(0.23) Up From $(0.30) YoY Benzinga

04:07PM EDT Regulus Therapeutics Reports Second Quarter 2020 Financial Results and Recent PR Newswire

Aug 6, 2020

08:07AM EDT Regulus Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual PR Newswire

Aug 3, 2020

08:07AM EDT Regulus Therapeutics Appoints Denis Drygin, Ph.D., as Chief Scientific Officer PR Newswire

Jul 29, 2020

08:13AM EDT Regulus Therapeutics Announces FDA Orphan Drug Designation Of RGLS4326 For ADPKD Treatment RTTNews

08:09AM EDT Regulus Therapeutics Announces FDA Orphan Drug Designation For RGLS4326 For Treatment Of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Benzinga

08:07AM EDT Regulus Therapeutics Announces FDA Orphan Drug Designation of RGLS4326 for the PR Newswire

Jul 22, 2020

08:15AM EDT Regulus Therapeutics Completes Dosing In Phase 1 Multiple Ascending Dose Study Of RGLS4326 RTTNews

08:11AM EDT Regulus Therapeutics Completes Dosing In Phase 1 Multiple Ascending Dose Study Of RGLS4326 In Healthy Volunteers For The Treatment Of Autosomal Dominant Polycystic Kidney Disease Benzinga

08:07AM EDT of RGLS4326 in Healthy Volunteers for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire

Share